April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer

April 3, 2023

$1.67B

$170M

n/a

n/a

Up to $1.5B in development, regulatory, and sales milestone payments.

Single-digit to double-digit tiered royalties.

DualityBio retains a co-development/co-promotion cost and profit/loss sharing option for DB-1311 in the U.S. market.

DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.

Dev and Commercial License

Co-Development, Shared Dev Cost , Co-Promotion, Shared Promotion Cost , Options to Add Products, TAs, and/or Territories

• DualityBio granted BioNTech exclusive, worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
• DualityBio has the option to co-develop and co-promote DB-1311 in the U.S. with cost and profit/loss sharing.
• DualityBio will receive $170M up front and is eligible for up $1.5B in development, regulatory, and sales milestones, plus single-digit to double-digit tiered royalties.